局限期小细胞肺癌预防性颅脑照射利用的影响因素
该研究回顾性分析了本单位208例接受根治性治疗的局限期小细胞肺癌患者,55%接受了预防性颅脑照射(PCI)。未行PCI最常见原因为患者因担心神经毒性而拒绝(38%),其次为医生评估医学上不适合(33%)和高龄(8%)。Karnofsky体能状态和临床AJCC分期与总生存显著相关,而PCI不是。
要点
- 约半数局限期小细胞肺癌患者最终接受PCI,多数符合指南推荐。
- 未行PCI最常见原因是患者担心神经毒性而拒绝。
- 减少PCI神经毒性的措施可能提高符合条件的患者中PCI的使用。
核心结论
- 约半数局限期小细胞肺癌患者最终接受PCI,通常基于指南推荐的原因。
- 未行PCI最常见原因是患者对神经毒性的担忧。
- 减少PCI神经毒性的努力(如海马保护放疗和美金刚)可能增加该生存改善干预在符合条件的局限期小细胞肺癌患者中的使用。
研究设计与样本
- 回顾性综述本单位所有接受根治性治疗的局限期小细胞肺癌患者。
- 共检查208例在本机构接受治疗的局限期小细胞肺癌患者。
- 采用Kaplan-Meier法估计总生存和脑转移累积发生率。
- 采用Pearson χ2检验和Mann-Whitney U检验检查与PCI使用相关的因素。
- 采用Cox比例风险模型分析预后因素。
主要发现
- 115例患者(55%)接受了PCI。
- 未行PCI最常见记录原因为患者因担心神经毒性而拒绝(38%)。
- 医生评估医学上不适合为第二位常见原因(33%),高龄为第三位(8%)。
- Karnofsky体能状态和临床AJCC分期与总生存显著相关,而PCI不是。
- 多因素分析中仅临床分期为独立因素。
临床怎么用
- 对局限期小细胞肺癌根治性治疗后反应良好的患者,应评估PCI适应证并讨论神经毒性风险。
- 患者拒绝PCI常因神经毒性担忧,可考虑海马保护放疗和美金刚等减少神经毒性的策略。
- 医生评估医学不适合和高龄是未行PCI的常见原因,需个体化评估获益风险。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain metastases are common in patients with limited-stage small cell lung cancer (LS-SCLC) due to the inability of most chemotherapeutics to penetrate the blood-brain barrier. Prophylactic cranial irradiation (PCI) is therefore recommended for use in patients with a good response to concurrent chemoradiotherapy. However, PCI is not always delivered; therefore, we investigated the reasons for PCI omission in patients who underwent therapy with curative intent. METHODS AND MATERIALS: We retrospectively reviewed all patients with LS-SCLC who were treated with curative intent at our institution. Overall survival and cumulative incidence of brain metastasis were estimated by the Kaplan-Meier method. The Pearson χ2 test and Mann-Whitney U test were used to examine factors associated with PCI use, and prognostic factors were analyzed with Cox proportional hazards modeling. RESULTS: We examined 208 patients who were treated for LS-SCLC at our institution. A total of 115 patients (55%) received PCI. The most common documented reason for PCI omission was patient refusal due to neurotoxicity concerns (38%). Physician assessment of being medically unfit (33%) and of advanced age (8%) were the second and third most common reasons, respectively. Karnofsky performance status and clinical American Joint Committee on Cancer stage but not PCI were significantly associated with overall survival. Only clinical stage remained an independent factor on multivariate analysis. CONCLUSIONS: Approximately half of patients with LS-SCLC ultimately receive PCI, generally for guideline-recommended reasons. The most common reason for PCI omission was patient concerns regarding neurotoxicity. Efforts to decrease PCI neurotoxicity, including hippocampal-sparing radiation and memantine use, may increase the use of this survival-improving intervention in eligible patients with LS-SCLC.
引用
- Lok BH, Ma J, Foster A, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Adv Radiat Oncol. 2017. PMID: 29204521. doi:10.1016/j.adro.2017.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。